About Carmot
Carmot is a company based in Berkeley (United States) founded in 2008 was acquired by Roche in December 2023. Carmot has raised $385.52 million across 17 funding rounds from investors including Amgen, Roche and HHS. Carmot operates in a competitive market with competitors including Adocia, Altimmune, BioAge Labs, Fractyl and Antag Therapeutics, among others.
- Headquarter Berkeley, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Carmot Therapeutics Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Carmot
Carmot has successfully raised a total of $385.52M across 17 strategic funding rounds. The most recent funding activity was a Series E round of $150 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Carmot
Carmot has secured backing from 19 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Amgen, Roche and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Deep Track Capital is engaged in biotechnology investment activities.
|
Locked | Locked | Locked | |
|
Venture capital fund backed incubator focused on the healthcare startups
|
Locked | Locked | Locked | |
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked |
Investor details for Carmot
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Carmot
Investment portfolio details for Carmot
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Carmot
Detailed financials for Carmot
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Carmot Comparisons
Peer comparison for Carmot
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Carmot
Carmot operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adocia, Altimmune, BioAge Labs, Fractyl and Antag Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
Bioinformatics platform is provided for biomarkers and drug discovery.
|
|
| Locked | Locked | Locked |
Endoscopic procedures for type-2 diabetes treatment are developed.
|
|
| Locked | Locked | Locked |
Peptide-based therapies for obesity and cardiometabolic disorders are developed.
|
Detailed competitors of Carmot
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Carmot
Complete news archive for Carmot
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Carmot
Carmot was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Carmot is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Heather Turner is the current CEO of Carmot.
Carmot is a funded company, having raised a total of $385.52M across 17 funding rounds to date.
The company was founded in 2008 in Berkeley, United States, and focuses on biotechnology for metabolic disorders. A drug discovery platform is utilized to identify incretin receptor signaling targets, supporting a pipeline of therapeutics aimed at obesity and diabetes. Three clinical candidatesCT-388, CT-868, and CT-996are advanced through development stages. Operations center on innovative treatments without emphasis on broader services.
Carmot's top competitors include Adocia, BioAge Labs and Fractyl.
Carmot has 19 investors. Key investors include Amgen, Roche, HHS, Schroders, and Janus Henderson Investors.